Navigate Fool.com
Will IMGN beat
the market?



Community Rating: 4 Stars: Favorite

13.79 -0.11 (-0.79%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.96
Previous Close $13.90
Daily Range $13.25 - $14.17
52-Week Range $11.78 - $20.25
Market Cap $1.2B
P/E Ratio -37.57
Dividend (Yield) $0.00 (0.0%)
Volume 764,385
Average Daily Volume 990,745
Current FY EPS -$0.72

How do you think IMGN
will perform against the market?

Top IMGN Bull/Bear Pitches


TMFBreakerThiel (< 20)
Submitted September 28, 2010

Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has … More

0 Replies Reply Report this Post

NetscribeHealthC (< 20)
Submitted February 14, 2007

ImmunoGen develops therapeutics for the treatment of cancer. The company’s tumor-activated prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to treat cancer cel … More

0 Replies Reply Report this Post

News & Commentary

The Fool Looks Ahead

Let's look at the stocks that will be making news in the week ahead.

Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks

The Beige Book release and key economic data pumps up the S&P 500 while Zogenix, ImmunoGen, and voxeljet lead individual stocks to the upside.

Wednesday Sector Leaders: Biotechnology, Rubber & Plastics

Wednesday's ETF Movers: FBT, GDX

Why ImmunoGen Inc. Shares Took Flight

ImmunoGen shares bounce after receiving fresh coverage from Wall Street. Find out what shareholders should really be focused on following this new rating.

Milestone Payments Push ImmunoGen to a Q2 Profit

A number of amortized milestone and licensing payments help push ImmunoGen to a surprise quarterly profit.

Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea

Morning movers in healthcare

Sector Update: Healthcare Shares Flat Pre-Market; ImmunoGen up 4% on Q4 Results

Sector Update: Healthcare

GlaxoSmithKline and Personalized Medicine Take Another Leap Forward

GlaxoSmithKline recently won an accelerated approval for the first combination melanoma therapy. This relatively easy label expansion holds important lessons for pharmaceutical companies, and investors.

See More IMGN News...





ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website: http://www.immunogen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks